# OnCo record paper-solo-1-nejm-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-solo-1-nejm-2018" ;
schema:name "SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer"@en ;
schema:description "In women with newly diagnosed advanced BRCA-mutated ovarian cancer who had responded to chemotherapy, two years of the PARP inhibitor olaparib kept far more of them free of progression than placebo, and the effect persisted for years after the tablets stopped. It moved PARP inhibitors into first-line maintenance and made BRCA testing at diagnosis routine."@en ;
schema:url ;
schema:dateModified "2026-09-08"^^xsd:date ;
schema:citation , ;
schema:sameAs ;
schema:datePublished "2018"^^xsd:gYear ;
schema:author "Moore K, Colombo N, Scambia G, et al." ;
onco:cancers ;
onco:technologies , , ;
onco:targets , ;
onco:drugs ;
onco:companies , ;
onco:terms , , , , ;
onco:people , ;
onco:bottlenecks , , ;
onco:journals .